The new inhibitor of monoamine oxidase, M30, has a neuroprotective effect against dexamethasone-induced brain cell apoptosis

Frontiers in Neuroscience

Volumn 4, Issue NOV, 2010, Pages

  Johnson, Shakevia ^a   Tazik, Shawna ^a   Lu, Deyin ^a   Johnson, Chandra ^a   Youdim, Moussa B H ^b,c   Wang, Junming ^a   Rajkowska, Grazyna ^a   Ou, Xiao Ming ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Yonsei University   (South Korea)

Author keywords

Apoptosis; Glucocorticoids; M30; Monoamine oxidase inhibitor; Neuroblastoma; Neuroprotection; Rasagiline; Selegiline

Indexed keywords

EID: 84863805122     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2010.00180     Document Type: Article

References (42)

1. Alexander-Kaufman, K., James, G., Sheedy, D., Harper, C., and Matsumoto, I. (2006). Differential protein expression in the prefrontal white matter of human alcoholics: a proteomics study. Mol. Psychiatry 11, 56-65.
2. Arguelles, S., Herrera, A. J., Carreno-Muller, E., de Pablos, R. M., Villaran, R. F., Espinosa-Oliva, A. M., Machado, A., and Cano, J. (2010). Degeneration of dopaminergic neurons induced by thrombin injection in the substantia nigra of the rat is enhanced by dexamethasone: role of monoamine oxidase enzyme. Neurotoxicology 31, 55-66.
3. Bar-Am, O., Weinreb, O., Amit, T., and Youdim, M. B. (2009). The neuroprotective mechanism of 1-(R)- aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J. Neurochem. 112, 1131-1137.
4. Carlo, P., Violani, E., Del Rio, M., Olasmaa, M., Santagati, S., Maggi, A., and Picotti, G. B. (1996). Monoamine oxidase B expression is selectively regulated by dexamethasone in cultured rat astrocytes. Brain Res. 711, 175-183.
5. Carlsson, A., Adolfsson, R., Aquilonius, S. M., Gottfries, C. G., Oreland, L., Svennerholm, L., and Winblad, B. (1980). Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism. Adv. Biochem. Psychopharmacol. 23, 295-304.
6. Chen, J. J., and Ly, A. V. (2006). Rasagiline: a second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. Am. J. Health Syst. Pharm. 63, 915-928.
7. de Kloet, E. R., Reul, J. M., and Sutanto, W. (1990). Corticosteroids and the brain. J. Steroid Biochem. Mol. Biol. 37, 387-394.
8. Duval, F., Mokrani, M. C., Monreal-Ortiz, J. A., Fattah, S., Champeval, C., Schulz, P., and Macher, J. P. (2006). Cortisol hypersecretion in unipolar major depression with melancholic and psychotic features: dopaminergic, noradrenergic and thyroid correlates. Psychoneuroendocrinology 31, 876-888.
9. Fernandez, H. H., and Chen, J. J. (2007). Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin. Neuropharmacol. 30, 150-168.
10. Gal, S., Abassi, Z. A., and Youdim, M. B. (2009). Limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30. Neurotox. Res. 18, 143-150.
11. Gal, S., Zheng, H., Fridkin, M., and Youdim, M. B. (2005). Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem. 95, 79-88.
12. Gal, S., Zheng, H., Fridkin, M., and Youdim, M. B. (2010). Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox. Res. 17, 15-27.
13. Haynes, L. E., Barber, D., and Mitchell, I. J. (2004). Chronic antidepressant medication attenuates dexamethasone-induced neuronal death and sublethal neuronal damage in the hippocampus and striatum. Brain Res. 1026, 157-167.
14. Hughes, B. (2008). New hope for Parkinson's disease progression delay. Nat. Rev. Drug Discov. 7, 791.
15. Jahng, J. W., Kim, N. Y., Ryu, V., Yoo, S. B., Kim, B. T., Kang, D. W., and Lee, J. H. (2008). Dexamethasone reduces food intake, weight gain and the hypothalamic 5-HT concentration and increases plasma leptin in rats. Eur. J. Pharmacol. 581, 64-70.
16. Kieran, N., Ou, X. M., and Iyo, A. H. (2010). Chronic social defeat downregulates the 5-HT1A receptor but not Freud-1 or NUDR in the rat prefrontal cortex. Neurosci. Lett. 469, 380-384.
17. Kupershmidt, L., Weinreb, O., Amit, T., Mandel, S., Carri, M. T., and Youdim, M. B. (2009). Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 23, 3766-3779.
18. Lee, A. L., Ogle, W. O., and Sapolsky, R. M. (2002). Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord. 4, 117-128.
19. Lu, D., Johnson, C., Johnson, S., Tazik, S., and Ou, X. M. (2008). The neuroprotective effect of antidepressant drug via inhibition of TIEG2-MAO B mediated cell death. Drug Discov. Ther. 2, 289-295.
20. Lyness, J. M., Yu, Q., Tang, W., Tu, X., and Conwell, Y. (2009). Risks for depression onset in primary care elderly patients: potential targets for preventive interventions. Am. J. Psychiatry 166, 1375-1383.
21. Malorni, W., Giammarioli, A. M., Matarrese, P., Pietrangeli, P., Agostinelli, E., Ciaccio, A., Grassilli, E., and Mondovi, B. (1998). Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett. 426, 155-159.
22. Manoli, I., Le, H., Alesci, S., McFann, K. K., Su, Y. A., Kino, T., Chrousos, G. P., and Blackman, M. R. (2005). Monoamine oxidase-A is a major target gene for glucocorticoids in human skeletal muscle cells. FASEB J. 19, 1359-1361.
23. Mao, Q. Q., Ip, S. P., Ko, K. M., Tsai, S. H., Xian, Y. F., and Che, C. T. (2009). Effects of peony glycosides on mice exposed to chronic unpredictable stress: further evidence for antidepressant-like activity. J. Ethnopharmacol. 124, 316-320.
24. Meyer, J. H., Ginovart, N., Boovariwala, A., Sagrati, S., Hussey, D., Garcia, A., Young, T., Praschak-Rieder, N., Wilson, A. A., and Houle, S. (2006). Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry 63, 1209-1216.
25. Meyer, J. H., Wilson, A. A., Sagrati, S., Miler, L., Rusjan, P., Bloomfield, P. M., Clark, M., Sacher, J., Voineskos, A. N., and Houle, S. (2009). Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch. Gen. Psychiatry 66, 1304-1312.
26. Ou, X. M., Chen, K., and Shih, J. C. (2004). Dual functions of transcription factors, transforming growth factor-beta-inducible early gene (TIEG)2 and Sp3, are mediated by CACCC element and Sp1 sites of human monoamine oxidase (MAO) B gene. J. Biol. Chem. 279, 21021-21028.
27. Ou, X. M., Chen, K., and Shih, J. C. (2006). Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J. Biol. Chem. 281, 21512-21525.
28. Ou, X. M., Lu, D., Johnson, C., Chen, K., Youdim, M. B., Rajkowska, G., and Shih, J. C. (2009a). Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox. Res. 16, 148-159.
29. Ou, X. M., Stockmeier, C. A., Meltzer, H. Y., Overholser, J. C., Jurjus, G. J., Dieter, L., Chen, K., Lu, D., Johnson, C., Youdim, M. B., Austin, M. C., Luo, J., Sawa, A., May, W., and Shih, J. C. (2009b). A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage. Biol. Psychiatry. 67, 855-863.
30. Phillips, A. J., Sudbery, I., Ramsdale, M. (2003). Apoptosis induced by environmental stresses and amphotericin B in Candida albicans. Proc. Natl. Acad. Sci. U. S. A. 100, 14327-14332.
31. Sacher, J., Wilson, A. A., Houle, S., Rusjan, P., Hassan, S., Bloomfield, P. M., Stewart, D. E., and Meyer, J. H. (2010). Elevated brain monoamine oxidase A binding in the early postpartum period. Arch. Gen. Psychiatry 67, 468-474.
32. Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., Schneider, L. S., and Thal, L. J. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 336, 1216-1222.
33. Shih, J. C., Chen, K., and Ridd, M. J. (1999). Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci. 22, 197-217.
34. Slotkin, T. A., Seidler, F. J., and Ritchie, J. C. (1998). Effects of aging and glucocorticoid treatment on monoamine oxidase subtypes in rat cerebral cortex: therapeutic implications. Brain Res. Bull. 47, 345-348.
35. Tazik, S., Johnson, S., Lu, D., Johnson, C., Youdim, M. B., Stockmeier, C. A., and Ou, X. M. (2009). Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotox. Res. 15, 284-290.
36. Youdim, M. B. (2006). The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr. Alzheimer Res. 3, 541-550.
37. Youdim, M. B., and Weinstock, M. (2002). Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mech. Ageing Dev. 123, 1081-1086.
38. Youdim, M. B., Gross, A., and Finberg, J. P. (2001). Rasagiline [N-propargyl-1R( + )-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 132, 500-506.
39. Youdim, M. B., Bar Am, O., Yogev-Falach, M., Weinreb, O., Maruyama, W., Naoi, M., and Amit, T. (2005). Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res. 79, 172-179.
40. Yu, S., Patchev, A. V., Wu, Y., Lu, J., Holsboer, F., Zhang, J. Z., Sousa, N., and Almeida, O. F. (2010). Depletion of the neural precursor cell pool by glucocorticoids. Ann. Neurol. 67, 21-30.
41. Zheng, H., Gal, S., Weiner, L. M., Bar-Am, O., Warshawsky, A., Fridkin, M., and Youdim, M. B. (2005). Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 95, 68-78.
42. Zhu, W., Xie, W., Pan, T., Xu, P., Fridkin, M., Zheng, H., Jankovic, J., Youdim, M. B., and Le, W. (2007). Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J. 21, 3835-3844.